Gatineau, November 19, 2025 — The Competition Bureau has expanded its investigation into BWX Technologies’ completed acquisition of Kinectrics after obtaining new court orders requiring Novartis and certain subsidiaries to provide records tied to nuclear medicine products supplied in Canada.
The Bureau is examining whether the transaction may substantially lessen or prevent competition in the nuclear medicine sector. BWX Technologies and Kinectrics operate at several stages of the medical isotope value chain, and the authority is assessing whether the deal could reduce supply or raise prices for isotopes vital for cancer treatments.
The Federal Court granted the latest orders as part of the Bureau’s broader use of compulsory investigative tools. These follow earlier orders issued to other suppliers of inputs used in the development of nuclear medical isotopes. BWX Technologies closed its acquisition of Kinectrics on May 20, 2025.
The investigation remains ongoing, and the Bureau has not reached any conclusions.
